{"nctId":"NCT03125902","briefTitle":"A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)","startDateStruct":{"date":"2017-08-25","type":"ACTUAL"},"conditions":["Triple-Negative Breast Cancer"],"count":653,"armGroups":[{"label":"Placebo and Paclitaxel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody","Drug: Paclitaxel"]},{"label":"Atezolizumab and Paclitaxel","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab Placebo","Drug: Paclitaxel"]}],"interventions":[{"name":"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody","otherNames":["MPDL3280A, TECENTRIQ"]},{"name":"Atezolizumab Placebo","otherNames":[]},{"name":"Paclitaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants with locally advanced or metastatic, histologically documented TNBC (absence of human epidermal growth factor receptor 2 \\[HER2\\], estrogen receptor \\[ER\\], and progesterone receptor \\[PR\\] expression), not amenable to surgical therapy\n* Participants eligible for taxane monotherapy\n* No prior chemotherapy or targeted systemic therapy (including endocrine therapy) for inoperable locally advanced or metastatic TNBC\n* Availability of formalin-fixed paraffin-embedded (FFPE) tumor block (preferred) or at least 17 unstained slides, collected â‰¤3 months prior to randomization, with an associated pathology report, if available. If a tumour sample taken within 3 months before randomisation is not available and a tumour biopsy is not clinically feasible, the primary surgical resection sample or the most recent FFPE tumour biopsy sample may be used. Of these additional options, the most recent sample should be used.\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Life expectancy at least 12 weeks\n* Measurable disease, as defined by RECIST v1.1\n* Adequate hematologic and end-organ function\n* Negative human immunodeficiency virus (HIV) test at screening.\n* Negative hepatitis B surface antigen (HBsAg) test at screening\n* Negative total hepatitis B core antibody (HBcAb) test at screening, or positive HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. The HBV DNA test will be performed only for patients who have a positive HBcAb test.\n* Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.\n* Women of child bearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study drug\n* For men and women of child bearing potential: agreement to remain abstinent or use protocol defined contraceptive measures during the treatment period and for at least 5 months after the last dose of atezolizumab/placebo, or for at least 6 months after the last dose of paclitaxel\n\nExclusion Criteria:\n\n* Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 2 weeks prior to randomization\n* Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases\n* Leptomeningeal disease\n* Uncontrolled pleural effusion, pericardial effusion, or ascites\n* Uncontrolled tumor-related pain, or uncontrolled hypercalcemia or clinically significant (symptomatic) hypercalcemia\n* Malignancies other than TNBC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer)\n* Pregnant or breast-feeding women, or intending to become pregnant during the study\n* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease, cardiovascular disease, and presence of an abnormal electrocardiogram (ECG)\n* Serious infection requiring antibiotics within 2 weeks prior to randomization, including but not limited to infections requiring hospitalization or IV antibiotics, such as bacteremia, or severe pneumonia\n* Major surgical procedure within 4 weeks prior to randomization or anticipation of the need for a major surgical procedure during the study other than for diagnosis\n* Treatment with investigational therapy within 30 days prior to initiation of study treatment\n* History of hypersensitivity reactions to study drug or any component of the study drug formulation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status","description":"PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first. PD is defined as greater than or equal to (\\>/=) 20 percent (%) relative increase and \\>/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.72","spread":null},{"groupId":"OG001","value":"5.95","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population","description":"PFS is defined as the time from randomization to the first occurrence of PD, as determined by the investigator using RECIST v1.1, or death from any cause during the study, whichever occurs first. PD is defined as greater than or equal to (\\>/=) 20 percent (%) relative increase and \\>/=5 millimeter (mm) of absolute increase in the sum of diameters (SD) of target lesions (TLs), taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.55","spread":null},{"groupId":"OG001","value":"5.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) in the PD-L1-Positive Subpopulation","description":"OS is defined as the time from randomization to death from any cause. Results from a pre-specified interim analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.29","spread":null},{"groupId":"OG001","value":"22.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) in the ITT Population","description":"OS is defined as the time from randomization to death from any cause. Results from a pre-specified interim analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.80","spread":null},{"groupId":"OG001","value":"19.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Alive at 12 and 18 Months","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.47","spread":null},{"groupId":"OG001","value":"68.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.18","spread":null},{"groupId":"OG001","value":"52.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Global Health Status/ Health Related Quality of Life (HRQoL) in the PRO Evaluable Population","description":"Deterioration in Global Health Status/HRQoL is defined as a decrease of at least 10 points on the Global Health Status /HRQoL scale (comprised of 2 items: 29 and 30) of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The 2 items use 7-point scale (1 = very poor to 7 = Excellent). Scores are averaged, transformed to 0-100 scale; where higher score=better level of functioning or greater degree of symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.35","spread":null},{"groupId":"OG001","value":"28.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Alive Without Progression Event at Month 12 Assessed Using RECIST v1.1","description":"PD is defined as \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.22","spread":null},{"groupId":"OG001","value":"21.63","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Population (Confirmed, Investigator-Assessed )","description":"Objective response is defined as complete response (CR) or partial response (PR), as determined by the investigator using RECIST v1.1 criteria. CR is defined as the disappearance of all TLs and SA reduction to less than (\\<) 10mm for nodal TLs/ non-TLs. PR is defined as \\>/=30% decrease in SD of TLs, taking as reference the baseline SD. Responses were confirmed after 8 weeks if within first 12 months or after 12 weeks if later.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"49.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Population (Unconfirmed, Investigator-Assessed)","description":"Objective response is defined as complete response (CR) or partial response (PR), as determined by the investigator using RECIST v1.1 criteria. CR is defined as the disappearance of all TLs and SA reduction to less than (\\<) 10mm for nodal TLs/ non-TLs. PR is defined as \\>/=30% decrease in SD of TLs, taking as reference the baseline SD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"63.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the Response-Evaluable Population (Confirmed, Investigator-Assessed )","description":"Objective response is defined as complete response (CR) or partial response (PR), as determined by the investigator using RECIST v1.1 criteria. CR is defined as the disappearance of all TLs and SA reduction to less than (\\<) 10mm for nodal TLs/ non-TLs. PR is defined as \\>/=30% decrease in SD of TLs, taking as reference the baseline SD. Responses were confirmed after 8 weeks if within first 12 months or after 12 weeks if later.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"39.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the Response-Evaluable Population (Unconfirmed, Investigator-Assessed )","description":"Objective response is defined as complete response (CR) or partial response (PR), as determined by the investigator using RECIST v1.1 criteria. CR is defined as the disappearance of all TLs and SA reduction to less than (\\<) 10mm for nodal TLs/ non-TLs. PR is defined as \\>/=30% decrease in SD of TLs, taking as reference the baseline SD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null},{"groupId":"OG001","value":"53.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Objective Response (DOR) Assessed Using RECIST v1.1 in DOR-evaluable Population (Unconfirmed)","description":"DOR is defined as the time period from the date of initial CR or PR until the date of PD or death from any cause, whichever occurs first. CR is defined as the disappearance of all TLs and SA reduction to \\<10mm for nodal TLs/ non-TLs. PR is defined as \\>/=30% decrease in SD of TLs, taking as reference the baseline SD. PD is defined as \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.45","spread":null},{"groupId":"OG001","value":"6.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Benefit Assessed Using RECIST v1.1 in Response-evaluable Population","description":"Clinical benefit is defined as the achievement of CR, PR, or stable disease according to RECIST v1.1 that lasts for at least 6 months. CR is defined as the disappearance of all TLs and SA reduction to \\<10mm for nodal TLs/ non-TLs. PR is defined as \\>/=30% decrease in SD of TLs, taking as reference the baseline SD. PD is defined as \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions. Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference smallest SD since treatment started.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.8","spread":null},{"groupId":"OG001","value":"57.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab in PK Evaluable Population","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":"53.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":"78.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"242","spread":"84.8"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Serum Concentration (Cmax) of Atezolizumab in PK-evaluable Population","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"321","spread":"90.5"}]}]}]},{"type":"SECONDARY","title":"Minimum Observed Plasma Concentration (Cmin) of Paclitaxel","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.51","spread":"NA"},{"groupId":"OG001","value":"1.67","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax) of Paclitaxel","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"518","spread":"290.7"},{"groupId":"OG001","value":"301","spread":"1501"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"666","spread":"339"},{"groupId":"OG001","value":"276","spread":"1360"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)","description":"Investigator text for AEs is coded using MedDRA version 25.1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Drug Antibodies' (ADAs) Against Atezolizumab in ADA Evaluable Population","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival by PD-L1 Status, Intent to Treat Population","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.30","spread":null},{"groupId":"OG001","value":"16.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.29","spread":null},{"groupId":"OG001","value":"22.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival by PD-L1 Status, Intent to Treat Population","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.49","spread":null},{"groupId":"OG001","value":"5.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.72","spread":null},{"groupId":"OG001","value":"5.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Confirmed Response (C-DoR) in (C-DoR)-Evaluable Population","description":"C-DoR is defined as the time from the first occurrence of a documented confirmed response (CR or PR) in C-DOR evaluable population until the date of disease progression per RECIST v1.1 or death from any cause, whichever occurs first. Responses were confirmed after 8 weeks if within first 12 months or after 12 weeks if later.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.75","spread":null},{"groupId":"OG001","value":"7.66","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":112,"n":431},"commonTop":["ALOPECIA","ANAEMIA","NEUROPATHY PERIPHERAL","DIARRHOEA","FATIGUE"]}}}